Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
暂无分享,去创建一个
Y G Meng | Y. Meng | N. Modi | Y. S. Lin | C. Nguyen | J. L. Mendoza | E. Escandón | D. Fei | Y S Lin | C Nguyen | J L Mendoza | E Escandon | D Fei | N B Modi | Jose Mendoza | Yvonne Lin | Yvonne S. Lin
[1] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[2] K. Alitalo,et al. Serum vascular endothelial growth factor is often elevated in disseminated cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] O. Vinante,et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.
[4] G. Scagliotti,et al. Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. , 1996, European journal of cancer.
[5] J. Fox,et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.
[6] G. Martiny-Baron,et al. Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates. , 1996, Clinical chemistry.
[7] M. Toi,et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] T. Nose,et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.
[9] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E S Gragoudas,et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.
[11] J. Folkman. Clinical Applications of Research on Angiogenesis , 1995 .
[12] S. Kondo,et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. , 1995, Cancer research.
[13] T. Lavé,et al. Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. , 1995, Journal of pharmaceutical sciences.
[14] R K Jain,et al. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.
[15] C. Davis,et al. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[16] R. Warren,et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.
[17] Anthony J. Guidi,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.
[18] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[19] S. Sasaki,et al. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. First communication: plasma concentration, distribution, metabolism and excretion of the new monoclonal antibody, regavirumab after intravenous administration in rats and rabbits. , 1994, Arzneimittel-Forschung.
[20] N. Olsen,et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.
[21] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[22] S. Sugawara,et al. The preclinical safety evaluation of human monoclonal antibody against cytomegalovirus. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[23] J. Winer,et al. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. , 1992, The Journal of clinical investigation.
[24] J. Mordenti,et al. Extrapolation of Toxicological and Pharmacological Data from Animals to Humans , 1991 .
[25] P. Familletti,et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. , 1991, Journal of immunology.
[26] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[27] J. Mordenti,et al. Man versus beast: pharmacokinetic scaling in mammals. , 1986, Journal of pharmaceutical sciences.
[28] W. Beierwaltes,et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] M. Gibaldi,et al. Pharmacokinetics, Second Edition , 1982 .